A new study has been released that provides some evidence that the anti-cancer medication ups the odds of congestive heart failure in these patients.
The meta-analysis, published online Jan. 4 in the Journal of Clinical Oncology, included almost 4,000 patients and found a small but significant number developed .
ast month, the U.S. Food and Drug Administration announced plans to revoke approval of bevacizumab (Avastin) for treating breast cancer, although not for other indications. The move was based on evidence that the drug doesn't prolong overall survival in and poses a risk of serious side effects.
Read more here.